Walgreen and CVS Are Looking Healthy

Although it is not known as a huge growth industry, drugstore chains seem to be holding up just fine in a tough economic environment. Is now the time to invest in them?

May 12, 2014 at 6:05PM

While earnings season has been a bit of a mixed bag for retailers, with several companies blaming their lackluster sales for the period on the extreme winter weather, some industries have been holding up just fine. For instance, big pharmacy chains have been delivering solid results recently; and with a steadily aging population increasingly dependent on drugs and medical care as well as an increased number of Americans now covered under the Affordable Care Act, this trend looks set to continue. Let's take a look at recent results from major drugstore chains Walgreen (NASDAQ:WBA) and CVS Caremark (NYSE:CVS).


Source: WikiMedia Commons

The biggest is still growing
Walgreen is America's largest drugstore chain, boasting more than 8,650 retail locations. Over the last few months, the company has been reporting some encouraging sales figures. In March, it saw overall sales growth of 4.5%, with pharmacy sales soaring nearly 9%. Moreover, comp-store sales were up a comfortable 3.5%.

The company's second-quarter earnings were less than inspiring, with earnings per share down by around 5% year over year. But the stock was still up more than 4% following the report, largely due to strong revenue growth. Sales for the quarter were up 5.1% on a 4.3% comp-store sales increase. According to management, the bottom line was pressured by a mild flu season and an aggressive discounting environment over the holiday period.

In any case, the latest read was very positive. April sales jumped 8.8% to nearly $6 billion, with customers spending around 6% more per visit. Pharmacy sales, which accounted for some 64.5% of total revenue, rose by 9.2%. The outlook for the current quarter is fairly rosy, with EPS expected to climb by around 9% and revenue by 5%.

CVS Caremark focuses on healthy living
CVS Caremark has been reporting some decent results of its own lately. While EPS missed the analyst consensus by $0.02, quarterly profits rose a very impressive 18% year over year for the fifth consecutive quarter of double-digit earnings growth. Revenue of approximately $32.7 billion was up 6.3% and came in stronger than the $32.3 billion consensus. According to management, the company does not usually blame the weather but made an exception this time as the effects were impossible to ignore.

Pharmacy sales were the driver behind these results, up more than 10% for the period. The chain, like its competitors, is also getting a boost from higher drug prices in general and is benefiting particularly from growth in its generic-drug segment. Generics generally have higher margins than branded medication, which is helping the bottom line.

Following a general trend in the industry, the company is working on becoming more of a health-care provider, adding in-store clinics and increasing collaboration with physicians and hospitals. CVS also drew a great deal of admiration for its decision to stop selling cigarettes, which is certainly more in keep with promoting a healthy lifestyle.

Valuations and metrics
One area of concern going forward is industry valuations. While CVS Caremark is trading at a more or less reasonable 19 times trailing earnings, Walgreen is starting to look pricey at 24.6. However, in terms of price to sales, both still look inexpensive at about 0.7 and 0.9, respectively. Both chains appear to have solid balance sheets, and both have comparable growth figures and margins. However, looking at valuations, CVS Caremark seems like the better deal.

The bottom line
Overall, the drugstore industry looks like it's in good shape. Moreover, demographics are working in their favor, as is the Affordable Care act. Walgreen and CVS Caremark, the two biggest drugstore chains in America, are both doing a good job of growing the top and bottom lines. However, CVS Caremark looks like the more compelling choice at the moment due to its lower valuation and double-digit earnings growth.

Your credit card may soon be completely worthless
The plastic in your wallet is about to go the way of the typewriter, the VCR, and the 8-track tape player. When it does, a handful of investors could stand to get very rich. You can join them -- but you must act now. An eye-opening new presentation reveals the full story on why your credit card is about to be worthless -- and highlights one little-known company sitting at the epicenter of an earth-shaking movement that could hand early investors the kind of profits we haven't seen since the dot-com days. Click here to watch this stunning video.


Daniel James has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information